BIOMARIN PHARMACEUTICAL INC Paid-in-Kind Interest
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Paid-in-Kind Interest of $7.34 million for the 3-month period ending 2016-03-31, per its 10-Q filed 2016-05-02.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2016-05-02
- BIOMARIN PHARMACEUTICAL INC paid-in-kind interest for the quarter ending 2016-03-31 was $7.34M, a 4.81% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC paid-in-kind interest for the quarter ending 2015-12-31 was $7.25M, a 4.77% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC paid-in-kind interest for the quarter ending 2015-09-30 was $7.16M, a 4.72% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC paid-in-kind interest for the quarter ending 2015-06-30 was $7.08M, a 4.63% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC paid-in-kind interest for fiscal 2015 was $28.49M, a 4.66% increase from fiscal 2014.
- BIOMARIN PHARMACEUTICAL INC paid-in-kind interest for fiscal 2014 was $27.23M, a 363.40% increase from fiscal 2013.
- BIOMARIN PHARMACEUTICAL INC paid-in-kind interest for fiscal 2013 was $5.88M, a 511.98% increase from fiscal 2012.
- BIOMARIN PHARMACEUTICAL INC paid-in-kind interest for fiscal 2012 was $960.00K, a 8.40% decline from fiscal 2011.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month | Paid-in-Kind Interest 12 month as first filed |
|---|---|---|---|---|---|
| 2016-03-31 | $7.34M 10-Q · filed 2016-05-02 | $14.59M derived: sum of 2 quarters · filed 2016-05-02 | $21.75M derived: sum of 3 quarters · filed 2016-05-02 | $28.83M derived: sum of 4 quarters · filed 2016-05-02 | |
| 2015-12-31 | $7.25M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $14.41M derived: sum of 2 quarters · filed 2016-02-29 | $21.49M derived: sum of 3 quarters · filed 2016-02-29 | $28.49M 10-K · filed 2016-02-29 | |
| 2015-09-30 | $7.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | $14.24M derived: sum of 2 quarters · filed 2015-11-02 | $21.24M 10-Q · filed 2015-11-02 | $28.16M derived: sum of 4 quarters · filed 2016-05-02 | |
| 2015-06-30 | $7.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $14.08M 10-Q · filed 2015-08-05 | $21.00M derived: sum of 3 quarters · filed 2016-05-02 | $27.84M derived: sum of 4 quarters · filed 2016-05-02 | |
| 2015-03-31 | $7.00M 10-Q · filed 2016-05-02 | $13.92M derived: sum of 2 quarters · filed 2016-05-02 | $20.76M derived: sum of 3 quarters · filed 2016-05-02 | $27.53M derived: sum of 4 quarters · filed 2016-05-02 | |
| 2014-12-31 | $6.92M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $13.76M derived: sum of 2 quarters · filed 2016-02-29 | $20.53M derived: sum of 3 quarters · filed 2016-02-29 | $27.23M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $6.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | $13.61M derived: sum of 2 quarters · filed 2015-11-02 | $20.30M 10-Q · filed 2015-11-02 | $25.83M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-06-30 | $6.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $13.46M 10-Q · filed 2015-08-05 | $18.99M derived: sum of 3 quarters · filed 2016-02-29 | $19.05M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-03-31 | $6.70M 10-Q · filed 2015-05-05 | $12.22M derived: sum of 2 quarters · filed 2016-02-29 | $12.28M derived: sum of 3 quarters · filed 2016-02-29 | $12.36M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2013-12-31 | $5.52M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $5.59M derived: sum of 2 quarters · filed 2016-02-29 | $5.66M derived: sum of 3 quarters · filed 2016-02-29 | $5.88M 10-K · filed 2016-02-29 | |
| 2013-09-30 | $63.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | $136.00K derived: sum of 2 quarters · filed 2014-10-28 | $352.00K 10-Q · filed 2014-10-28 | ||
| 2013-06-30 | $73.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $289.00K 10-Q · filed 2014-07-31 | |||
| 2013-03-31 | $216.00K 10-Q · filed 2014-05-02 | ||||
| 2012-12-31 | $960.00K 10-K · filed 2015-03-02 | ||||
| 2011-12-31 | $1.05M 10-K · filed 2014-02-26 | $0.00 10-K · filed 2012-02-22 | |||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | $0.00 derived: sum of 2 quarters · filed 2012-02-22 | $0.00 10-K · filed 2012-02-22 | ||
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-29 | $0.00 10-Q · filed 2010-10-29 | |||
| 2010-06-30 | $0.00 10-Q · filed 2010-08-04 | ||||
| 2009-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | -$282.00K derived: sum of 2 quarters · filed 2012-02-22 | $2.58M 10-K · filed 2012-02-22 | ||
| 2009-09-30 | -$282.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-29 | $2.58M 10-Q · filed 2010-10-29 | |||
| 2009-06-30 | $2.86M 10-Q · filed 2010-08-04 | ||||
| 2008-12-31 | $4.38M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |